Tags

Type your tag names separated by a space and hit enter

Nanoformulation of Biogenic Cefotaxime-Conjugated-Silver Nanoparticles for Enhanced Antibacterial Efficacy Against Multidrug-Resistant Bacteria and Anticancer Studies.
Int J Nanomedicine. 2020; 15:1889-1901.IJ

Abstract

OBJECTIVES

Due to the expanded bacterial genetic tolerance to antibiotics through different mechanisms, infectious diseases of MDR bacteria are difficult for treatment. Consequently, we synthesized drug conjugated nanoparticles to dissolve this problem. Moreover, the present study aims to display the cell death status treated with cefotaxime-CS-AgNPs and also, apoptosis pathways of human RPE-1 normal cells and human MCF-7 breast cancer cells.

METHODS

Here, we demonstrate the possibility to synthesize AgNPs and conjugate them with cefotaxime to survey the probability of cefotaxime-CS-AgNPs as an antimicrobial agent against cefotaxime-resistant strains E. coli and MRSA.

RESULTS

TEM showed the size of AgNPs, CS-AgNPs and cefotaxime-CS-AgNPs ranged from 7.42 to 18.3 nm, 8.05-23.89 nm and 8.48-25.3 nm, respectively, with a spherical shape. The cefotaxime-CS-AgNPs enhanced the high antimicrobial properties compared to AgNPs or pure antibiotic. The MIC of Cefotaxime-CS-AgNPs ranged from 3 µg/mL to 8 µg/mL against tested E. coli and MRSA bacteria. Consequently, the highest reduction in the MIC of cefotaxime-CS-AgNPs was noted against tested strains ranging from 22% to 96%. Comparing cefotaime-CS-AgNPs to AgNPs we showed that cefotaime-CS-AgNPs have no cytotoxic effect on normal cells at even 12 µg/mL for 24 hrs. The IC50 for the AgNPs and cefotaxime-CS-AgNPs was 12 µg/mL for human RPE-1 normal cells and human MCF-7 breast cancer cell lines. The pro-apoptotic genes p53, p21, and Bax of cancer cell lines significantly upregulated followed by downregulated by anti-apoptotic gene Bcl-2 after 48 hrs at 24 µg/mL, and this concentration represents the most effective dose.

CONCLUSION

Results enhanced the conjugating utility in old unresponsive cefotaxime to AgNPs to restore its efficiency against previous strains and demonstrated potential therapeutic applications of cefotaxime-CS-AgNPs. Moreover, this research gives remarkable insights for designing nanoscale delivery and curative systems that have a pronounced cytotoxic activity on cancer cells and are safe to normal cells.

Links

PMC Free PDF

Authors+Show Affiliations

Halawani EM
Division of Microbiology, Department of Biology, Faculty of Science, Taif University, Taif 21974, Saudi Arabia. Yousef Abdullatif Jameel Chair of Prophetic Medicine Application, King Abdulaziz University, Jeddah, Saudi Arabia.
Hassan AM
Department of Biotechnology, Faculty of Science, Taif University, Taif 21974, Saudi Arabia. Cell Biology Department, National Research Centre, Dokki, Giza, Egypt.
Gad El-Rab SMF
Department of Biotechnology, Faculty of Science, Taif University, Taif 21974, Saudi Arabia. Department of Botany and Microbiology, Faculty of Science, Assiut University, Assiut 71516, Egypt.

MeSH

Anti-Bacterial AgentsAntineoplastic AgentsApoptosisCefotaximeCell Line, TumorDrug Resistance, Multiple, BacterialEscherichia coliGene Expression RegulationHumansMCF-7 CellsMetal NanoparticlesMethicillin-Resistant Staphylococcus aureusMicrobial Sensitivity TestsSilverSpectrophotometry, UltravioletSpectroscopy, Fourier Transform InfraredX-Ray Diffraction

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32256066

Citation

Halawani, Eman M., et al. "Nanoformulation of Biogenic Cefotaxime-Conjugated-Silver Nanoparticles for Enhanced Antibacterial Efficacy Against Multidrug-Resistant Bacteria and Anticancer Studies." International Journal of Nanomedicine, vol. 15, 2020, pp. 1889-1901.
Halawani EM, Hassan AM, Gad El-Rab SMF. Nanoformulation of Biogenic Cefotaxime-Conjugated-Silver Nanoparticles for Enhanced Antibacterial Efficacy Against Multidrug-Resistant Bacteria and Anticancer Studies. Int J Nanomedicine. 2020;15:1889-1901.
Halawani, E. M., Hassan, A. M., & Gad El-Rab, S. M. F. (2020). Nanoformulation of Biogenic Cefotaxime-Conjugated-Silver Nanoparticles for Enhanced Antibacterial Efficacy Against Multidrug-Resistant Bacteria and Anticancer Studies. International Journal of Nanomedicine, 15, 1889-1901. https://doi.org/10.2147/IJN.S236182
Halawani EM, Hassan AM, Gad El-Rab SMF. Nanoformulation of Biogenic Cefotaxime-Conjugated-Silver Nanoparticles for Enhanced Antibacterial Efficacy Against Multidrug-Resistant Bacteria and Anticancer Studies. Int J Nanomedicine. 2020;15:1889-1901. PubMed PMID: 32256066.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Nanoformulation of Biogenic Cefotaxime-Conjugated-Silver Nanoparticles for Enhanced Antibacterial Efficacy Against Multidrug-Resistant Bacteria and Anticancer Studies. AU - Halawani,Eman M, AU - Hassan,Aziza M, AU - Gad El-Rab,Sanaa M F, Y1 - 2020/03/18/ PY - 2019/10/26/received PY - 2020/02/20/accepted PY - 2020/4/8/entrez PY - 2020/4/8/pubmed PY - 2020/7/28/medline KW - AgNPs and cefotaxime-Cs-AgNPs KW - E. coli KW - MRSA KW - anticancer KW - cytotoxicity KW - genotoxicity SP - 1889 EP - 1901 JF - International journal of nanomedicine JO - Int J Nanomedicine VL - 15 N2 - OBJECTIVES: Due to the expanded bacterial genetic tolerance to antibiotics through different mechanisms, infectious diseases of MDR bacteria are difficult for treatment. Consequently, we synthesized drug conjugated nanoparticles to dissolve this problem. Moreover, the present study aims to display the cell death status treated with cefotaxime-CS-AgNPs and also, apoptosis pathways of human RPE-1 normal cells and human MCF-7 breast cancer cells. METHODS: Here, we demonstrate the possibility to synthesize AgNPs and conjugate them with cefotaxime to survey the probability of cefotaxime-CS-AgNPs as an antimicrobial agent against cefotaxime-resistant strains E. coli and MRSA. RESULTS: TEM showed the size of AgNPs, CS-AgNPs and cefotaxime-CS-AgNPs ranged from 7.42 to 18.3 nm, 8.05-23.89 nm and 8.48-25.3 nm, respectively, with a spherical shape. The cefotaxime-CS-AgNPs enhanced the high antimicrobial properties compared to AgNPs or pure antibiotic. The MIC of Cefotaxime-CS-AgNPs ranged from 3 µg/mL to 8 µg/mL against tested E. coli and MRSA bacteria. Consequently, the highest reduction in the MIC of cefotaxime-CS-AgNPs was noted against tested strains ranging from 22% to 96%. Comparing cefotaime-CS-AgNPs to AgNPs we showed that cefotaime-CS-AgNPs have no cytotoxic effect on normal cells at even 12 µg/mL for 24 hrs. The IC50 for the AgNPs and cefotaxime-CS-AgNPs was 12 µg/mL for human RPE-1 normal cells and human MCF-7 breast cancer cell lines. The pro-apoptotic genes p53, p21, and Bax of cancer cell lines significantly upregulated followed by downregulated by anti-apoptotic gene Bcl-2 after 48 hrs at 24 µg/mL, and this concentration represents the most effective dose. CONCLUSION: Results enhanced the conjugating utility in old unresponsive cefotaxime to AgNPs to restore its efficiency against previous strains and demonstrated potential therapeutic applications of cefotaxime-CS-AgNPs. Moreover, this research gives remarkable insights for designing nanoscale delivery and curative systems that have a pronounced cytotoxic activity on cancer cells and are safe to normal cells. SN - 1178-2013 UR - https://www.unboundmedicine.com/medline/citation/32256066/Nanoformulation_of_Biogenic_Cefotaxime_Conjugated_Silver_Nanoparticles_for_Enhanced_Antibacterial_Efficacy_Against_Multidrug_Resistant_Bacteria_and_Anticancer_Studies_ DB - PRIME DP - Unbound Medicine ER -